Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

BioArctic Partner Eisai Launches Leqembi Pen in Japan

By Public Technologies
  • BioArctic's partner Eisai launched Leqembi Pen in Japan for early Alzheimer's disease on November 13, 2026.
  • Japan is the second launch market following the US; the treatment is now included in Japan's national health insurance drug price list.
  • Japanese approval came on September 16, 2026, making it the country's first anti-amyloid treatment available for home administration.
  • The autoinjector delivers a weekly 500 mg dose using two pens, offering an alternative to intravenous treatment every two weeks.
  • BioArctic receives royalties on global sales and sales milestone payments, with no lecanemab development costs for Alzheimer's disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.